Baatarkhuu Oidov, Kim Do Young, Nymadawa Pagbajabyn, Kim Seung Up, Han Kwang-Hyub, Amarsanaa Jazag, Gonchigsuren Dagvasumberel, Sanduijav Ravjir, Lkhagvasuren Zundui, Khorolsuren Naran, Oyungerel Ravjir, Ahn Sang Hoon
Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, South Korea.
Department of Infectious Diseases, Health Sciences University, Ulaanbaatar, Mongolia.
Hepatol Int. 2012 Oct;6(4):763-9. doi: 10.1007/s12072-011-9325-4. Epub 2011 Nov 30.
Hepatocellular carcinoma (HCC) is the most common cancer in Mongolia. We aimed to investigate the clinical features, therapeutic modalities, overall survival and prognostic factors for Mongolian patients with HCC.
One hundred ninety-five patients with HCC were consecutively enroled in our study.
The mean age was 61.7 years. The most common etiology for HCC was HCV infection (n = 89, 45.6%), followed by HBV infection (n = 67, 34.4%). The mean tumor diameter was 6.0 ± 2.6 cm. Only 29 (14.9%) patients had a single lesion, while 39 (20.2%) had >3 lesions. Extrahepatic metastasis to lung (n = 23), bone (n = 10) and lymph node (n = 3) were detected in 36 (18.5%) patients. Most patients had advanced HCC-88 (45.1%) in stage III and 57 (29.2%) in stage IV. Surgical resection was performed in 27 (13.8%) patients, RFA in 23 (11.8%) and TACE in 107 (54.9%). When all the patients were categorized as 'treated' (n = 156) and 'not treated' (n = 39), the 3-year survival was significantly lower in the 'not treated' group than in the 'treated' group (11 vs. 0%, P < 0.001). Tumor diameter (<3 cm vs. ≥3 cm), extrahepatic metastasis, TNM stage (I/II vs. III/IV) and treatment (or supportive care) were selected as independent predictors for survival.
High proportion of patients with HCC in Mongolia is diagnosed at an advanced stage and survival of these patients is lower compared to other countries. A surveillance system and referral policy for high-risk groups should be urgently established and implemented in Mongolia.
肝细胞癌(HCC)是蒙古最常见的癌症。我们旨在调查蒙古HCC患者的临床特征、治疗方式、总生存期和预后因素。
195例HCC患者连续纳入我们的研究。
平均年龄为61.7岁。HCC最常见的病因是丙型肝炎病毒(HCV)感染(n = 89,45.6%),其次是乙型肝炎病毒(HBV)感染(n = 67,34.4%)。平均肿瘤直径为6.0±2.6 cm。仅29例(14.9%)患者有单个病灶,而39例(20.2%)患者有超过3个病灶。36例(18.5%)患者检测到肝外转移至肺(n = 23)、骨(n = 10)和淋巴结(n = 3)。大多数患者为晚期HCC - 88例(45.1%)处于III期,57例(29.2%)处于IV期。27例(13.8%)患者接受了手术切除,23例(11.8%)接受了射频消融(RFA),107例(54.9%)接受了经动脉化疗栓塞(TACE)。当将所有患者分为“接受治疗”(n = 156)和“未接受治疗”(n = 39)两组时,“未接受治疗”组的3年生存率显著低于“接受治疗”组(11%对0%,P < 0.001)。肿瘤直径(<3 cm对≥3 cm)、肝外转移、TNM分期(I/II期对III/IV期)和治疗(或支持治疗)被选为生存的独立预测因素。
蒙古HCC患者中很大比例在晚期被诊断出来,与其他国家相比,这些患者的生存率较低。蒙古应紧急建立并实施针对高危人群的监测系统和转诊政策。